The truth is out there: An overall perspective on androgen deprivation

Beth A. Hellerstedt, Kenneth J. Pienta

Research output: Contribution to journalArticlepeer-review

Abstract

Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.

Original languageEnglish (US)
Pages (from-to)272-281
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Volume21
Issue number4
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Keywords

  • ADT
  • Adjuvant
  • Cost
  • LHRH agonist
  • Neoadjuvant

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'The truth is out there: An overall perspective on androgen deprivation'. Together they form a unique fingerprint.

Cite this